Brainstorm Cell Therapeutics (BCLI) investor relations material

Executive summary

• Focused on developing autologous cell therapies for neurodegenerative diseases, with NurOwn® as the lead candidate for ALS, PMS, and AD.

• Advanced pre-initiation activities for the Phase 3b ENDURANCE trial of NurOwn in ALS after FDA clearance, aiming to enroll 200 participants with a 24-week double-blind and 24-week open-label extension period.

• Engaged with clinical sites, manufacturing partners, and regulatory authorities to ensure operational readiness for the upcoming trial.

• A Citizen Petition was filed with the FDA by ALS community representatives, requesting renewed regulatory review of NurOwn data; the company acknowledged but did not participate in the petition.

• Company delisted from Nasdaq in July 2025 due to non-compliance with minimum shareholder equity, now trading on OTCQB.

Financial highlights

• Net loss for Q3 2025 was $2.1M, down from $2.7M in Q3 2024; net loss for nine months ended September 30, 2025 was $7.9M, down from $8.7M year-over-year.

• Operating expenses for nine months ended September 30, 2025 were $7.7M, down from $8.5M year-over-year.

• Cash, cash equivalents, and restricted cash at September 30, 2025 totaled $236K.

• Net cash used in operating activities for nine months ended September 30, 2025 was $6.2M; net cash provided by financing activities was $6.1M.

• Net loss per share for Q3 2025 was $0.19, improved from $0.51 in Q3 2024.

Outlook and guidance

• Management expects continued operating losses and negative cash flow from clinical and regulatory activities.

• Additional capital will be required to fund Phase 3b ALS trial and commercialization efforts.

• Uncertainty remains regarding the ability to raise future financing, especially after delisting from Nasdaq.

• Planning to host a conference call and webcast in late Q4 2025 or early Q1 2026 to provide further updates on the NurOwn Phase 3 program.